SCHEMBL26310077

SCHEMBL26310077

NC(=O)C[C@@H](N)C(=O)NCCc1ccccn1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.52
ATM Q13315 1/20 0.52
MAPK1 P28482 1/20 0.51
KMT2A Q03164 3/20 0.51
NPY1R P25929 1/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
MEN1 O00255 2/20 0.48
ALDH1A1 P00352 1/20 0.48
RAB9A P51151 3/20 0.48
NPC1 O15118 2/20 0.48
TAS1R3 Q7RTX0 1/20 0.48
TAS1R1 Q7RTX1 1/20 0.48
CNR1 P21554 1/20 0.48
TLR2 O60603 1/20 0.48
L3MBTL1 Q9Y468 2/20 0.47
HSD11B1 P28845 1/20 0.47
LMNA P02545 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
HRH3 Q9Y5N1 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8917140 0.83 HTT (0.51) HTTATMMAPK1KMT2ANPY1R
SCHEMBL10558453 0.82 HTT (0.62) HTTATMMAPK1KMT2ASMN1; SMN2
SCHEMBL4986522 0.80 HTT (0.56) HTTATMMAPK1KMT2ANPY1R
SCHEMBL5666551 0.80 HTT (0.53) HTTATMMAPK1KMT2ASMN1; SMN2
SCHEMBL30206599 0.79 MAPK1 (0.60) HTTMAPK1KMT2ASMN1; SMN2MEN1
SCHEMBL2755853 0.79 MAPK1 (0.60) HTTMAPK1KMT2ASMN1; SMN2MEN1
SCHEMBL24095980 0.79 CA12 (0.53) KMT2ACNR1
SCHEMBL8210490 0.79 CA12 (0.53) KMT2ACNR1
SCHEMBL8210487 0.79 CA12 (0.53) KMT2ACNR1
SCHEMBL10311684 0.79 HTT (0.64) HTTATMMAPK1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234917-A1 ASPARAGINE DERIVATIVES AND METHODS OF USING SAME SENDA BIOSCIENCES INC (US) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234917-A1 ASPARAGINE DERIVATIVES AND METHODS OF USING SAME ASNS, SI, NARS1 HTT 998/4885ATM 1013/4885MAPK1 4235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.